Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from TOT BIOPHARM International Co. Ltd. ( (HK:1875) ).
BioDlink International Company Limited has appointed Grand Moore Capital Limited as the independent financial adviser to its Independent Board Committee in connection with a voluntary conditional cash offer by WuXi XDC Cayman Inc. to acquire all issued shares not already owned by the offeror and to cancel all outstanding share options. The adviser will opine on whether the terms of the offers are fair and reasonable and on the appropriate response for shareholders and option holders, with its advice to be included in a forthcoming composite document; the company also cautioned investors that completion of the offers remains subject to conditions and may not proceed, urging stakeholders to await the committee’s recommendations and exercise prudence in trading the company’s securities.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited is a Hong Kong-incorporated company listed on the Hong Kong Stock Exchange under stock code 1875. Its board comprises an executive director, a non-executive director and three independent non-executive directors, reflecting a typical governance structure for a listed firm subject to Hong Kong securities regulation and the Takeovers Code.
Average Trading Volume: 1,874,849
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.29B
For a thorough assessment of 1875 stock, go to TipRanks’ Stock Analysis page.